|
 The company's supervisory board was due to discuss and vote on the
settlement, which includes a $2 billion buffer for future claims, in
the coming days, paper cited company and negotiating partner sources
as saying.
A spokesman for Bayer declined to comment on the report. Perry Weitz
of Weitz & Luxenberg, one of the leading plaintiffs' firms involved
in the Roundup litigation, also would not comment.
The drugs and pesticides group, which said in May that talks were
progressing, is keen to draw a line under the legal dispute, which
it inherited via its $63 billion takeover of Monsanto in 2018.
[to top of second column] |
In April, Bayer's management regained shareholder support for its handling of
the litigation process.
Bayer's shares rose 5.7% to 72.52 euros at 1045 GMT.
Bayer said in April it has been served with cases in court from 52,500 U.S.
plaintiffs who blame Roundup and other glyphosate-based weedkillers for their
cancer, up from 48,600 in February.
(Reporting by Ludwig Burger, Madeline Chambers and Patricia Weiss; editing by
Thomas Seythal and Louise Heavens)
[© 2020 Thomson Reuters. All rights
reserved.] Copyright 2020 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |
